...
首页> 外文期刊>Expert Review of Molecular Diagnostics >Molecular diagnostic testing for primary biliary cholangitis
【24h】

Molecular diagnostic testing for primary biliary cholangitis

机译:原发性胆源性胆管炎的分子诊断测试

获取原文
获取原文并翻译 | 示例

摘要

Introduction: A reliable liver autoimmune serology for the diagnosis of primary biliary cholangitis (PBC) is of particular importance. Recognition of patients at early stages and prompt treatment initiation may alter the outcome, slow progression, delays liver failure, and improves survival.Areas covered: In this review, we summarize and discuss the published data obtained from literature searches from PubMed and The National Library of Medicine (USA) and our own experience on the current and potential molecular based approaches to the diagnosis of PBC.Expert commentary: Standardization of liver diagnostic serology and clinical governance are two major points as antimitochondrial antibodies are the diagnostic hallmark of the disease and PBC-specific antinuclear antibodies could assist in the diagnosis and estimation of prognosis. New biomarkers such as novel autoantibodies, genetic polymorphisms, metabolomic profiling, micro-RNA and epigenetics may assist to the understanding, diagnosis and management of the disease.
机译:简介:对于原发性胆源性胆管炎(PBC)的诊断,可靠的肝脏自身免疫血清学尤为重要。早期识别患者并立即开始治疗可能会改变结果,进展缓慢,延缓肝衰竭并改善生存率。涵盖范围:在本综述中,我们总结并讨论了从PubMed和国家图书馆的文献检索中获得的公开数据(美国)和我们在目前和潜在的基于分子的方法诊断PBC方面的经验。专家评论:肝脏诊断血清学和临床治理的标准化是两个主要方面,因为线粒体抗体是该疾病和PBC的诊断标志特异性抗核抗体可以帮助诊断和评估预后。新的生物标志物,例如新型自身抗体,遗传多态性,代谢组学谱,微RNA和表观遗传学,可能有助于理解,诊断和控制该疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号